Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
PTC Therapeutics, Inc.

PTC Therapeutics, Inc. (PTCT) Stock Overview

Explore PTC Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

PTCT●NASDAQ
HealthcareBiotechnology
$68.92
$0.81(1.19%)
U.S. Market is Open · 15:17

PTC Therapeutics, Inc. (PTCT)

Meyka AI Score

Z

Key Financials

Market Cap5.8B
P/E Ratio-141.47
EPS (TTM)$-2.33
ROE0.22%
Fundamental Analysis

AI Price Forecasts

1 Month$80.20
3 Months$91.66
1 Year Target$87.68

PTCT Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of PTC Therapeutics, Inc. (NASDAQ: PTCT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, PTC Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of PTCT on the NASDAQ shows an RSI of 31.64, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $87.68 for the NASDAQ listing.

Key metrics behind PTC Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -141.47 and a market capitalization of 5.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of PTCT on the NASDAQ.

Price Performance (NASDAQ: PTCT)

1-Day Change
1.45%
5-Day Change
-5.85%
1-Month Change
-19.12%
3-Month Change
5.51%
6-Month Change
-6.51%
Year-to-Date (YTD) Change
-9.03%
1-Year Change
32.25%
3-Year Change
78.51%
5-Year Change
79.57%
All-Time (Max) Change
319.04%

Contact Information

https://www.ptcbio.com
908 222 7000
500 Warren Corporate Center Drive, Warren, NJ, 07080

Company Facts

9,910 Employees
IPO DateJun 20, 2013
CountryUS
Actively Trading

Frequently Asked Questions